Two IPOs raised a combined $380 million this past week. Blank check company Capitol Investment Corp. IV led the way with a $350 million offering, and branded content curator Chicken Soup for the Soul Entertainment followed with a Reg A+ offering that raised $30 ...read more
Athenex, which is developing oral chemotherapies and kinase inhibitors for cancer in the US and China, raised $66 million by offering 6 million shares at $11, the low end of the range of $11 to $13. Athenex plans to list on the Nasdaq under the symbol ATNX....read more
There are three deals raising a total of $194 million on the calendar for the week ahead. Each deal is raising less than $100 million. The week’s two biotechs, Athenex and Avenue Therapeutics, are joined by a billboard owner, Boston Omaha. We...read more
US IPO Weekly Recap: A SPAC and a Reg A+ price; two billion-dollar companies file
Two IPOs raised a combined $380 million this past week. Blank check company Capitol Investment Corp. IV led the way with a $350 million offering, and branded content curator Chicken Soup for the Soul Entertainment followed with a Reg A+ offering that raised $30 ...read more
US IPO Weekly Recap: 2 small and pre-bought IPOs trade up
Find out why institutional investors rely on Renaissance Capital's Pre-IPO Research for these...read more
Cancer biotech Athenex prices IPO at $11, the low end of the range
Athenex, which is developing oral chemotherapies and kinase inhibitors for cancer in the US and China, raised $66 million by offering 6 million shares at $11, the low end of the range of $11 to $13. Athenex plans to list on the Nasdaq under the symbol ATNX....read more
US IPO Week Ahead: Billboards and biotechs with 3 small IPOs
There are three deals raising a total of $194 million on the calendar for the week ahead. Each deal is raising less than $100 million. The week’s two biotechs, Athenex and Avenue Therapeutics, are joined by a billboard owner, Boston Omaha. We...read more